Possible complementary treatment for patients with Parkinson's disease: Stimvia

Monday, June 10, 2024

Stimvia , a pioneering medical technology company specializing in neuromodulation for the treatment of chronic diseases, has successfully completed its pilot study focused on Parkinson's disease (PD) and expects promising results .

"We are pleased to share preliminary results that indicate promising results. Patients have reported improvements in both the number of Parkinson's disease symptoms and their overall quality of life. Additionally, we have observed a notable reduction in resting tremor. Although the precise data are still being rigorously evaluated, we remain cautiously optimistic about the potential implications of these results," said Prof. David Skoloudik , MD, Ph.D.,FESO, FEAN, study director and Vice Dean of Science and Research. from the Faculty of Medicine of the University of Ostrava.

Twelve patients with Parkinson's disease who met the inclusion criteria participated in the study. For six weeks, patients used the URIS® device in daily thirty-minute stimulation sessions. After this phase, patients spent six weeks without stimulation, during which they continued to be monitored to assess whether positive effects persisted after treatment ended.

"As URIS® technology has been shown to have a positive impact in the treatment of Parkinson's disease, Stimvia plans to make a substantial investment in further clinical trials to validate the efficacy and safety of the method. We believe that our technology can introduce new modalities of additive treatment options for millions of patients who currently have no other options, which could offer a positive disease-modifying impact for those suffering from Parkinson's disease," said Lukas Doskocil , CEO of Stimvia.

The company plans to treat a significant number of people with PD using its unique technology in the near future. In the United States alone, an estimated 1 million people suffer from these conditions, contributing to more than 10 million patients worldwide. Parkinson's disease is classified as the second most prevalent neurodegenerative disorder after Alzheimer's disease.

Full data from the pilot study will be revealed in the coming months. 

About Stimvia and URIS® Technology 

Stimvia is a pioneering clinical-stage medical technology company focused on the development and commercialization of innovative non-invasive therapies for chronic diseases. After years of research and a series of clinical studies, Stimvia has developed a unique technology known as URIS®, which includes the peroneal neuromodulation method (eTNM®). This pioneering approach marks the first non-invasive technique to stimulate deep brain structures, where many chronic diseases originate. Current clinical studies reveal  that Stimvia's technology is one of the most effective in treating conditions such as overactive bladder, which affects approximately 40 million people in the US.

The company's key technological components and methods are protected by more than 100 international patents in the EU, Japan, Russia and the USA. In addition, Stimvia is distinguished by prestigious certifications from the world-renowned German institution, TÜV SÜD.







Source: prnewswire.com